An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histological or cytological confirmation of metastatic and/or unresectable metastatic
colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with
measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per
PCWG3

- Presence of at least 2 lesions: at least one with measurable disease as defined by
RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response
assessment; at least 1 lesion must be accessible for biopsy in addition to the target
lesion

- Participants must have received, and then progressed or been intolerant to, at least 1
standard treatment regimen in the advanced or metastatic setting, if such a therapy
exists, and have been considered for all other potentially efficacious therapies prior
to enrollment

- ECOG performance status less than or equal to 2

Exclusion Criteria:

- Participants with active central nervous system (CNS) metastases, untreated CNS
metastases, or with the CNS as the only site of disease

- Participants with carcinomatous meningitis

- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study treatment

- Participants with active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply